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G protein-coupled receptor 119 (GPR119) is involved in regulating metabolic homoeostasis, with GPR119
agonists targeted for the treatment of type-2 diabetes and obesity. Using the endogenous agonist
oleoylethanolamide and a number of small molecule synthetic agonists we have investigated the tem-
poral dynamics of receptor signalling. Using both a dynamic luminescence biosensor-based assay and an
endpoint cAMP accumulation assay we show that agonist-driven desensitization is not a major reg-
ulatory mechanism for GPR119 despite robust activation responses, regardless of the agonist used.
Temporal analysis of the cAMP responses demonstrated sustained signalling resistant to washout for
some, but not all of the agonists tested. Further analysis indicated that the sustained effects of one
synthetic agonist AR-231,453 were consistent with a role for slow dissociation kinetics. In contrast, the
sustained responses to MBX-2982 and AZ1 appeared to involve membrane deposition. We also detect
wash-resistant responses to AR-231,453 at the level of physiologically relevant responses in an en-
dogenous expression system (GLP-1 secretion in GLUTag cells). In conclusion, our ﬁndings indicate that
in a recombinant expression system GPR119 activation is sustained, with little evidence of pronounced
receptor desensitization, and for some ligands persistent agonist responses continue despite removal of
excess agonist. This provides novel understanding of the temporal responses proﬁles of potential drug
candidates targetting GPR119, and highlights the importance of carefully examining the the mechanisms
through which GPCRs generate sustained responses.
& 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
GPR119 is a class A G protein-coupled receptor (GPCR) that
signals predominantly through cAMP via the stimulatory G-protein
(Gαs) (Lauffer et al., 2009; Syed et al., 2012). GPR119 demonstrates a
highly localized pattern of expression within the gastrointestinal
tract and pancreas (Lan et al., 2009; Lauffer et al., 2009; Soga et al.,
2005) consistent with a role in metabolic function. Endogenous
agonists for GPR119 are lipids such as oleoylethanolamine and
2-oleoyl glycerol, further supporting this role (Cornall et al., 2013;
Hansen et al., 2011; Syed et al., 2012). Indeed, stimulation of GPR119
is strongly linked with glucose homoeostasis with a direct effect onr B.V. This is an open access article
Alderley Park, Macclesﬁeld,
(J.D. Hothersall).insulin release from pancreatic β-cells, as well as an indirect effect
on insulin signalling via glucagon-like peptide 1 (GLP-1) release
from enteroendocrine cells (Chu et al., 2008, 2007; Soga et al.,
2005). For these reasons, the development of GPR119 agonists has
attracted considerable interest as potential pharmacotherapies for
type-2 diabetes and obesity (Cornall et al., 2013; Kang, 2013; Ohishi
and Yoshida, 2012). A number of chemically diverse synthetic
GPR119 agonists have been developed and characterized (Brockle-
hurst et al., 2011; Scott et al., 2012; Semple et al., 2008, 2011), with
four having advanced to clinical trials (Ohishi and Yoshida, 2012).
Typically, upon chronic agonist exposure GPCRs undergo de-
sensitization and internalization resulting in a loss of receptor
responsiveness over time (Drake et al., 2006; Kelly et al., 2008).
However, not all GPCR systems conform to this model of acute
agonist-mediated regulation. Some receptors have been reported
not to internalize and/or desensitize (Callander et al., 2009; Jensenunder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Fig. 1. Chemical structures of the agonists used in this study.
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demonstrated that when conventional desensitization mechan-
isms do not exert a major regulatory inﬂuence, sustained receptor
responses can be maintained with persistent agonist–receptor
interactions. Functionally, the consequences of this mechanism
have been deﬁned as sustained receptor activation even after re-
moval of excess agonist (Calebiro et al., 2009; Ferrandon et al.,
2009; Haskell-Luevano et al., 1996; Mullershausen et al., 2009).
Whilst some evidence for GPR119 desensitization has been pre-
viously reported (Kumar et al., 2014; Lauffer et al., 2009; Zhang
et al., 2014), a comprehensive characterization of desensitization
of GPR119 cAMP signalling has not yet been conducted. This key
gap in our understanding of GPR119 biology may be especially
pertinent to observations of tachyphylaxis and lack of efﬁcacy of
GPR119 agonists in the clinic (Kang, 2013).
In the present study we have investigated the chronic effects of
the endogenous GPR119 agonist oleoylethanolamide as well as the
synthetic agonists AR-231,453, GSK-1292263, MBX-2982, AZ1, AZ2,
and AZ3, as described previously (Brocklehurst et al., 2011; Scott
et al., 2012; Semple et al., 2008) and shown in Fig. 1. Using a re-
combinant expression system we ﬁnd that desensitization is not a
major regulatory inﬂuence. Additionally, some agonists demon-
strate sustained wash-resistant receptor activation, and we pro-
vide experimental evidence to support a role for slow dissociation
kinetics or membrane deposition in mediating these responses.2. Materials and methods
2.1. Materials
Cell culture materials were from Invitrogen. HTRF DynamiccAMP assay kit was from CisBio. Assay plates were from Greiner
Bio-One. GloSensor 22F plasmid DNA, GloSensor cAMP reagent,
and Profections mammalian transfection kit were from Promega.
GLP-1 ELISA was from Millipore. All synthetic GPR119 agonists
were synthesized at AstraZeneca. All other compounds and re-
agents were from Sigma-Aldrich (UK).
2.2. Cell culture and transfection
HEK-293 cells stably expressing human GPR119 (HEK-GPR119)
were maintained in Dulbecco's Modiﬁed Eagle Medium supple-
mented with 25 mM (D)-glucose, 4 mM L-alanyl-L-glutamine,
1 mM sodium pyruvate, 10% foetal calf serum and 800 mg/ml G-418
in an atmosphere of 5% CO2 at 37 °C. GLUTag cells were maintained
in Dulbecco's Modiﬁed Eagle Medium supplemented with 5.6 mM
(D)-glucose, 4 mM L-glutamine, 1 mM sodium pyruvate, 10% foetal
calf serum, 100 μg/ml streptomycin, and 100 I.U/ml penicillin. Cells
were transfected by the calcium phosphate method using the
Profections kit (Promega), as per the manufacturer's instructions.
In short, cells were plated onto 25 cm2 ﬂasks the day prior to
transfection to achieve approximately 75% conﬂuency. Culture
media was replaced 3 h before addition of DNA/CaPO4 complexes
(30 mg DNA per ﬂask) and then cells were incubated for a further
20 h at 37 °C. Culture media was replaced again before experi-
mentation 5–10 h later.
2.3. Dynamic GloSensor cAMP assay
2.3.1. Agonist responses
HEK-GPR119 cells were transfected with GloSensor 22F plasmid
(Promega) and used for dynamic cAMP measurements 24–30 h
later. Cell suspensions were made by dislodging the cells using PBS
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media. Cells were then washed twice by pelleting through cen-
trifugation (300g, 5 min) and resuspension in assay buffer (Hank's
Balanced Salt Solution supplemented with 20 mM HEPES and
0.01% fatty acid free BSA, pH 7.4). Cells were then counted and
diluted to 600,000 cells/ml in buffer, before GloSensor cAMP re-
agent was added (2% v/v) and equilibrated with the cells for 2 h at
20 °C with periodic mixing. 50 ml/well of cells were added to
white-bottomed 384 well plates (30,000 cells/well) in triplicate
and baseline luminescence was measuring using an Envision
plate-reader. 5 μl of test compound (serially diluted in DMSO and
then diluted 1:100 in assay buffer to obtain 10 concentrated
solution) was manually added to the assay wells to achieve the
stated ﬁnal concentration. Plates were incubated at 20 °C with
luminescence read at regular intervals to detect dynamic cAMP
changes over time within the same wells. cAMP responses at each
time-point were expressed as fold over control (vehicle-treated
cells).
2.3.2. GloSensor desensitization assay
Cells prepared as above were incubated with agonist (at in-
dicated concentrations) for 10 min at 20 °C. cAMP levels were then
measured by reading luminescence to determine maximal control
stimulation. In the continued presence of agonist, cells were then
incubated at 37 °C for 60 min, subsequently re-equilibrated to
20 °C (15 min), and cAMP levels then measured once more to
determine responsiveness after chronic agonist exposure in the
same population of cells.
2.4. Endpoint HTRF cAMP assay
2.4.1. Preparation of cells
HEK-GPR119 cells were grown to conﬂuency in ﬂasks, and cell
suspensions were made by dislodging cells using PBS wash and
accutase treatment followed by resuspension in culture media.
Cells were then washed twice by pelleting through centrifugation
(227g, 7 min, 20 °C) and resuspension in warm assay buffer
(Hank's Balanced Salt Solution supplemented with 20 mM HEPES
and 0.01% fatty acid free BSA, pH 7.4), with a 5 min incubation at
37 °C after the second wash. Cells were then counted and diluted
to 200,000 cells/ml in warm assay buffer.
2.4.2. cAMP capture and measurement
In cells prepared as above, cAMP accumulation was captured by
addition of the phosphodiesterase inhibitor 3-isobutyl-1-methyl-
xanthine (IBMX) at 1 mM with or without co-incubation of test
agonist for 45 min (unless otherwise stated) at 20 °C. Cellular
cAMP was then measured using the HTRF Dynamic competitive
immunoassay kit (CisBio), following the manufacturer's instruc-
tions. In short, 10 ml/well of cells were added to black-bottomed
384 well plates (2000 cells/well) in quadruplicate before addition
of 5 ml/well of dye-labelled cAMP diluted in lysis buffer, then ad-
dition of 5 ml/well of anti-cAMP antibody labelled with cryptate
diluted in lysis buffer, followed by incubation for 1–16 h (20 °C). To
construct a standard curve, samples of known cAMP concentration
were also incubated in the same way. Fluorescence was then read
at 665 and 620 nm using an Envision plate-reader, and a 665/620
ratio derived. Cellular cAMP concentration was calculated by
comparing these values (normalized to background ﬂuorescence)
to the standard curve for each plate.
2.4.3. “Chronic incubation/washout” protocol
To investigate the effects of chronic treatment with GPR119
agonists followed by removal of excess ligand by washing, the
“chronic incubation/washout” protocol was applied: 12 ml of cells
prepared as above (Section 2.4.1) were aliquoted into 15 ml tubesand test agonist was added (1:1000 dilution of compound serially
diluted in DMSO) before incubation at 37 °C for 60 min (in the
absence of IBMX), with periodic mixing. To remove excess ligand,
cells were washed three times by pelleting through centrifugation
(227g, 7 min, 4 °C) and resuspension in ice-cold buffer. Cells were
then resuspended in ice-cold buffer at 200,000 cells/ml and cAMP
capture and measurement was performed as described above.
Where indicated, a smaller volume of agonist pre-treatment buffer
was used (0.05 ml).
2.4.4. Inﬁnite dilution protocol
As an alternative approach to remove excess ligand after
chronic pre-treatment, inﬁnite dilution was used. This involved
chronically treating the cells with agonists (as above; Section
2.4.3) followed by centrifugation (227g, 7 min, 20 °C) and remov-
ing the bulk of the drug-containing buffer, followed by another
centrifugation step (227g, 4 min, 20 °C) and carefully removing the
remaining liquid. Cells were then resuspended in 12 ml fresh
buffer (20 °C) at approximately 200,000 cells/ml.
2.5. GLP-1 secretion in GLUTag cells
GLUTag cells were seeded onto poly-D lysine coated 96 well
plates at 8000 cells/well and grown for approximately 48 h. Cells
were incubated in assay buffer (Hank's Balanced Salt Solution
supplemented with a ﬁnal concentration of 10 mM (D)-glucose,
20 mM HEPES and 0.1% BSA, pH 7.4) containing test ligand (1:1000
dilution of compound serially diluted in DMSO) for 1 h at 37 °C.
Cells were then washed by four exchanges of fresh buffer, before
exposure to buffer containing the diepetidyl peptidase IV inhibitor
K-579 (100 nM)7test compound for 2 h at 37 °C. Supernatant was
then removed and GLP-1 concentration measured by the Millipore
ELISA kit, as per the manufacturers instructions. Fluorescence was
measured at abs/em of 355/460 nm using a Tecan Saﬁre, and
samples compared to a standard curve. Responses were normal-
ized to signal in control-treated cells.
2.6. Data analysis and statistics
Graphs were constructed and statistical analysis performed
using GraphPad Prism 4. Data are expressed as mean of a least
three separate experiments performed in triplicate (GloSensor
assay) or quadruplicate (Endpoint assay) plus and minus standard
error of mean. n, nn, and nnn indicate Po0.05, 0,01 and 0.001,
respectively with the indicated statistical test. ANOVA used one-
way ANOVA with Bonferroni post test. Concentration–response
analysis used the sigmoidal dose–response (variable slope)
function.3. Results
3.1. GPR119 responses to the endogenous agonist
oleoylethanolamide
To investigate GPR119 responses we used HEK293 cells stably
expressing the human GPR119 receptor (HEK-GPR119) as a model
system. Two complementary cAMP assays were used to monitor
receptor activation responses in these cells to more directly probe
speciﬁc aspects of chronic agonist effects. Firstly, the GloSensor
assay allowed the temporal analysis of cellular cAMP changes to be
measured in the same population of cells, supporting the char-
acterization of dynamic changes in receptor function with con-
tinued agonist treatment (without the inclusion of a phospho-
diesterase inhibitor). The endpoint assay was used to measure
total cellular cAMP accumulation over a single, deﬁned time-
Table 1
pEC50 values derived from concentration–response analysis in different GPR119
cAMP assays. All values represent pEC50 values7standard deviation (n¼3–6) de-
rived from sigmoidal concentration response using nonlinear regression with
variable slope. GloSensor responses were measured for 40 min at 20 °C (as shown
in Figs. 2A and 3A). Endpoint method 1 measured responses with 45 min agonist
plus IBMX incubation at 20 °C (Fig. 2A). Endpoint method 2 measured responses
with 60 min agonist incubation at 37 °C plus an additional 45 min plus IBMX at
20 °C (Fig. 5 A–D). Sustained responses were measured after 60 min agonist
incubation at 37 °C followed by multiple washing stages and then incubation with







Oleoylethanolamide 5.9470.05 6.7270.17 nt nt
AR-231,453 8.0370.13 7.7870.09 8.9370.17 8.6770.11
MBX-2982 8.3370.11 8.1270.12 8.7970.12 7.0370.13
GSK-1292263 7.8470.10 nt nt nt
AZ1 8.6470.10 8.5070.09 8.6170.09 6.6370.17
AZ2 7.7570.10 nt nt nt
AZ3 7.1670.05 nt nt nt
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diesterase inhibitor (1 mM IBMX), and supported the character-
ization of receptor function after ligand pre-exposure followed by
washout.
Initially, we investigated cAMP responses upon GPR119 sti-
mulation with the endogenous agonist oleoylethanolamide. HEK-
GPR119 cells transiently expressing GloSensor were incubated
with a range of concentrations of oleoylethanolamide for 40 min
at 20 °C. Concentration–response analysis derived a pEC50 of
5.9470.05 (Table 1) and a maximal response of 4.0570.45 fold
over basal (n¼3) (Fig. 2A).
Use of the GloSensor assay permitted measurement of dynamic
changes in cAMP over the time-course of agonist stimulation
(Fig. 2B). At the maximal concentration of 30 mM there was a
4.3570.73 fold increase in cAMP after 5 min exposure, and this
remained stable throughout the experiment. Responses to all
concentrations of oleoylethanolamide tested demonstrated a si-
milar activation proﬁle; there was no signiﬁcant loss of cAMP
signal over the time-course of the experiment (P40.05; ANOVA;
n¼3; comparing responses at 5 min to those thereafter).
These stable cAMP responses are consistent with a lack of
GPR119 desensitization upon oleoylethanolamide stimulation.
However, the measurements were made at a non-physiological
temperature which may inﬂuence normal cellular processes of
desensitization and internalization. Therefore, as a positive control
for putative GPCR desensitization responses in these cells, we in-
vestigated the temporal proﬁle of endogenous prostaglandin re-
ceptors signalling (Fig. 2C). Upon stimulation with 10 mM pros-
taglandin E2 this receptor demonstrated a signiﬁcant loss of signal
over time (Po0.05 or 0.01; ANOVA comparing responses after
5 min with those subsequent; n¼3) consistent with a fully intact
desensitization mechanism. Importantly, this PGE desensitization
occurred despite a lower level of cAMP generation (Fig. 2C) com-
pared to oleoylethanolamide responses (Fig. 2B) and therefore does
not appear to be a function of the magnitude of cAMP generated.
Further analysis of dynamic oleoylethanolamide responses at
37 °C demonstrated no loss of signal with time (Sup. Fig. S1).
However, the detection of robust and reproducible luminescence
signals were challenging at this temperature. To conﬁrm the lack of
desensitization with GPR119 at physiological temperature, we de-
signed an experiment that allowed measurement of GloSensor
cAMP responses at 20 °C before and after chronic incubation at
37 °C in the continued presence of agonist (GloSensor desensitiza-
tion assay). In this experiment, responses to oleoylethanolamide
(5 mM) were not lost after chronic exposure, (Fig. 2D), indicating
that no desensitization occurred even at physiological temperature.In fact, there was a small but signiﬁcant increase (Po0.05; ANOVA;
n¼3) in cAMP levels comparing the before and after responses to
oleoylethanolamide. In marked contrast, prostaglandin E2 (10 mM)
responses demonstrated robust desensitization with cAMP signals
signiﬁcantly reduced (Po0.001; ANOVA; n¼3; Fig. 2D) after
chronic exposure.
To further conﬁrm these effects, an endpoint cAMP assay was
also used to investigate GPR119 responses to oleoylethanolamide.
Concentration–response analysis in this assay after incubation
with oleoylethanolamide in the presence of IBMX for 45 min at
20 °C generated a pEC50 of 6.7270.17 M (Fig. 2A; Table 1). This
concentration–response curve is somewhat different to the Glo-
Sensor assay in both its potency (6.03 fold shift in EC50) and proﬁle
(slight “bell-shaped”).
To corroborate a lack of oleoylethanolamide-mediated GPR119
desensitization with the endpoint assay, we assessed receptor re-
sponsiveness after chronic pre-treatment with a maximally stimu-
lating concentration of oleoylethanolamide (1 mM) at 37 °C using the
“chronic incubation/washout” protocol (described in Section 2).
Compared to control cells, no loss of acute responsiveness was ob-
served after chronic pre-treatment with a maximal concentration of
oleoylethanolamide (P40.05; ANOVA; n¼3), consistent with no
desensitization (Fig. 2E). In oleoylethanolamide pre-treated cells
without subsequent re-stimulation, cAMP levels were not sig-
niﬁcantly different (P40.05; ANOVA; n¼3) to basal cAMP levels in
control cells, indicating that oleoylethanolamide was effectively re-
moved by washing. For comparison with the GloSensor assay, we
also tested the effect of chronic pre-treatment with 5 mM oleoy-
lethanolamide (which is supramaximal in the endpoint assay but
submaximal in the GloSensor assay). Acute cAMP responses were
signiﬁcantly lower than in oleoylethanolamide pre-treated cells than
in control cells (Po0.001; ANOVA; n¼4), indicating desensitization
upon chronic exposure to this concentration of oleoylethanolamide
(Fig. 2F). Therefore, it appears that at high concentrations there is an
assay-speciﬁc observation of GPR119 desensitization by oleoyletha-
nolamide, although importantly in both assays no desensitization is
observed at maximally stimulating concentrations (relevant to that
assay). PGE responses also demonstrated robust desensitization in
the endpoint assay (Sup. Fig. S2), indicating its applicability to
measure GPCR desensitization responses.
3.2. Acute GPR119 responses and lack of GPR119 desensitization
upon chronic exposure to synthetic agonists
Since GPR119 did not desensitize upon stimulation with an en-
dogenous agonists, we also wished to investigate whether this was the
case with a panel of synthetic agonists (AR-231,453, MBX-2982, GSK-
1292263, AZ1, AZ2, and AZ3; Fig. 1). We therefore ﬁrst characterized
the acute effects of these ligands by performing concentration–re-
sponse analysis in the GloSensor assay (40 min incubation at 20 °C)
(Fig. 3A). Derived pEC50 values are summarized in Table 1. Time-
courses of dynamic cAMP responses to these agonists at 20 °C (Sup.
Fig. S3) or 37 °C (Sup. Fig. S4) showed stable responses, consistent with
little desensitization at maximally stimulating concentrations. Con-
centration–response analysis was also determined for some agonists
using the endpoint assay after 45 min incubation with IBMX (Table 1),
and was found to be largely consistent with GloSensor.
We next directly investigated whether the synthetic agonists
could cause desensitization of GPR119 responses. Chronic ex-
posure at 37 °C of all six agonists at a supramaximal concentration
of 1 mM using the GloSensor desensitization assay did not cause
any signiﬁcant loss of response (Fig. 3B; P40.05; ANOVA; n¼3),
indicating an apparent lack of desensitization.
Additionally, we investigated desensitization with these ligands
(at 1 mM) in “chronic incubation/washout” experiments using the
endpoint assay. Comparing acute re-stimulation responses in
Fig. 2. GPR119 responses to stimulation by oleoylethanolamide. (A) Concentration–response analysis of oleoylethanolamide in the GloSensor (red curve) and endpoint (blue
curve) cAMP assays. In the GloSensor assay HEK-GPR119 cells transiently transfected with GloSensor plasmid were incubated with the indicated concentrations of oleoy-
lethanolamide for 40 min at 20 °C. In the endpoint assay, HEK-GPR119 cells were incubated with oleoylethanolamide and IBMX for 45 min at 20 °C. (B) Time-courses of
oleoylethanolamide responses using the GloSensor assay. Cells were incubated with the indicated concentrations of oleoylethanolamide at 20 °C and cAMP responses were
measured at the indicated time-points. Shown are representative concentrations of the full response curve presented in A. (C) Time-course of prostaglandin E2 responses
using the GloSensor assay. HEK-GPR119 cells transiently expressing GloSensor plasmid were incubated with 10 mM prostaglandin E22 at 20 °C and cAMP responses measured
over time. (D) GloSensor desensitization assay using r. Cells were incubated with 5 mM oleoylethanolamide or 10 mM prostaglandin E2 for 10 min at 20 °C and cAMP levels
measured (before; white bars). In the continued presence of agonist, cells were then incubated at 37 °C for 60 min before re-equilibration to 20 °C and cAMP levels measured
again (after; grey bars). (E, F) Desensitization assay using the endpoint cAMP assay. HEK-GPR119 cells were incubated with 1 mM (E) or 5 mM (F) oleoylethanolamide or
vehicle control (VEH) for 60 min at 37 °C before excess ligand was removed by washing. Cells were then re-stimulated with the same concentration of oleoylethanolamide
(stimulated; grey bars) or vehicle control (unstimulated; white bars) in the presence of IBMX for 45 min at 20 °C. (For interpretation of the references to colour in this ﬁgure
legend, the reader is referred to the web version of this article.)
J.D. Hothersall et al. / European Journal of Pharmacology 762 (2015) 430–442434control and agonist pre-treated cells, no signiﬁcant difference
(P40.05; ANOVA; n¼3–6) was observed for all agonists tested,
indicating no loss of responsiveness after chronic agonist treat-
ment.) (Fig. 3C). In summary, no evidence for GPR119 desensiti-
zation was found for all the agonists tested.3.3. Sustained wash-resistant cAMP responses to some GPR119
agonists
As GPR119 agonist responses are stable over time, factors that
prolong agonist/receptor interactions may lead to continual
Fig. 3. GPR119 responses to stimulation by synthetic agonists. (A) Concentration–response analysis of AR-231,453 (red), GSK-1292263 (orange), MBX-2982 (green), AZ1
(blue), AZ2 (indigo), and AZ3 (black) using the GloSensor cAMP assay with a 40 min incubation at 20 °C. (B) GloSensor desensitization assay. Cells were incubated with 1 mM
of the indicated agonist for 10 min at 20 °C and cAMP levels measured (before; white bars). In the continued presence of agonist, cells were then incubated at 37 °C for
60 min before re-equilibration to 20 °C and cAMP levels were measured again (after; grey bars). (C) Desensitization assay using the endpoint cAMP assay. Cells were
incubated with vehicle control (white bars) or 1 mM of the indicated agonist (grey bars) for 60 min at 37 °C before excess ligand was removed by washing. Cells were then re-
stimulated with 1 mM of the same agonist and responses in agonist pre-treated cells expressed as a percentage of basal cAMP levels. (For interpretation of the references to
colour in this ﬁgure legend, the reader is referred to the web version of this article.)
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we investigated if cAMP responses evoked by GPR119 agonists
were resistant to washing and thus sustained in nature. In the
same “chronic incubation/washout” experiments as described
above (Section 2.4.3), sustained responses were identiﬁed by an
increase in cAMP levels in cells that were pre-treated with agonist
but did not experience subsequent re-stimulation with agonist; i.e.
a residual effect of the agonist after washing (Fig. 4A). In cells pre-
treated with AR-231,453, MBX-2982, or AZ1 (1 mM) in “chronic
incubation/washout” experiments, cAMP accumulation captured
by IBMX inclusion was signiﬁcantly increased compared to control
cells (Po0.01; ANOVA; n¼3–6) despite extensive washing to re-
move excess agonist. In contrast, unstimulated cAMP levels in cells
pre-treated with GSK-1292263, AZ2, or AZ3 (1 mM) were not dif-
ferent to control, indicating that washing had successfully re-
moved the effect of these ligands. Compared to the acute cAMP
responses evoked by AR-231,453, MBX-2982, and AZ1 in control
cells, the sustained responses after “chronic incubation/washout”
were high at 101.38725.04%, 84.62720.22%, and 51.75718.61%
of acute, respectively (n¼3–6). Therefore, it appears that maximal
or near-maximal cAMP generation is achieved by prior exposure to
these agonists, despite removal of excess ligand by washing.
To directly assess whether these sustained wash-resistant
cAMP responses were caused by continual activation of the re-
ceptor after agonist washout we investigated the potential con-
tribution of newly synthesized cAMP to the total signal by mon-
itoring the temporal proﬁle of cAMP accumulation in the presence
of IBMX after agonist washout. Cells pre-treated with 1 mM AR-
231,453 or vehicle control (0.1% DMSO) in “chronic incubation/washout” experiments were incubated post-washout for 60 min at
20 °C in the presence of IBMX to enable the temporal proﬁle of
cAMP accumulation to be measured (Fig. 4B). Low cAMP levels
were observed in the absence of IBMX (6.9471.91% of maximal
response generated in the presence of IBMX at 60 min). This in-
dicates efﬁcient degradation of cAMP via phosphodiesterase me-
chanisms in these cells that is prevented by IBMX. Upon addition
of IBMX there was a robust time-dependent increase in cAMP
accumulation in AR-231,453 pre-treated cells, whilst in control
cells this increase was modest. These observations are consistent
with de novo cAMP synthesis occurring over the time-course of
IBMX addition and thus after removal of excess agonist. Therefore,
it appears that the receptor is continually activated by AR-231,453
after it has been washed out.
In order to address whether the sustained effects of AR-231,453
were modulated speciﬁcally through the GPR119 receptor agonist
binding, we investigated whether it was feasible to competitively
antagonize the sustained responses driven by other GPR119 li-
gands. For this study we used AZ2 which represents a potent
agonist (Table 1; Fig. 3A) that does not demonstrate a wash-re-
sistant activation proﬁle (Fig. 4A). The presence of saturating
concentrations of AZ2 would be predicted to occupy the GPR119
binding site thereby competitively inhibiting the binding of other
ligands during chronic pre-treatment. Pre-incubation with AZ2
(1 mM, 60 min, 37 °C) followed by treatment with 5 nM AR-231,453
in the continued presence of AZ2 (60 min, 37 °C), demonstrated
that AZ2 could inhibit the ability of AR-231,453 to exhibit a sus-
tained wash-resistant cAMP response (Fig. 4C). In cells pre-in-
cubated with AZ2 compared to control cells, sustained cAMP levels
Fig. 4. Sustained cAMP responses evoked by GPR119 agonists. (A) “Chronic incubation/washout” experiments using the endpoint cAMP assay. Cells were chronically pre-
treated with 1 mM of the indicated agonist for 60 min at 37 °C or with vehicle control. Excess ligand was then removed by washing and cells were subsequently incubated
with IBMX for 45 min at 20 °C to measure unstimulated cAMP levels. Responses are expressed as percentage of basal (unstimulated cAMP levels in control cells) (B) Time-
course of IBMX effects after removal of excess AR-231,453. Cells were pre-treated with or without AR-231,453 (1 mM, 60 min, 37 °C) and washed as above. Cells were then
incubated for 60 min with IBMX included for the indicated times during this period. cAMP responses are expressed as a percentage of maximum (the AR-231,453effect with
60 min IBMX inclusion). (C) Competitive antagonism of sustained agonist effects. Cells were pre-incubated with (grey bars) or without (white bars) AZ2 (1 mM, 60 min, 37 °C)
before subsequent chronic pre-treatment with AR-231,453 (5 nM, 60 min, 37 °C) or vehicle control. Excess ligand was removed by washing and cAMP was then captured in
the presence of IBMX (45 min) without subsequent re-stimulation to detect sustained responses.
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out” protocol) were signiﬁcantly reduced (Po0.05; ANOVA; n¼3)
and were comparable to basal levels of cAMP accumulation. These
data suggest that the sustained response driven by AR-231,453 can
be competitively inhibited by other GPR119 ligands, which is likely
consistent with the response being mediated speciﬁcally by the
same GPR119 binding site.
3.4. The stability and longevity of sustained GPR119 agonist
responses
To gain further insight into the stability of the agonist/receptor
interactions after washout we measured the concentration-de-
pendency of the sustained responses to AR-231,453, MBX-2982
and AZ1 in “chronic incubation/washout” experiments using the
endpoint assay and compared these to their acute stimulatory
effects (as shown previously in Fig. 5A–C and Table 1 method 2).
Under the same cAMP capture conditions, concentration–response
curves were generated after either previous exposure to agonist
followed by washout (sustained) or in the continued presence of
agonist without washout (acute). Based on the assumption that
concentration–response curves for acute and sustained responses
are reﬂective of agonist-mediated receptor activation before and
after washout, respectively, then the relationship between these
curves will be dependent on how much agonist/receptorinteraction is lost by washing (Table 1). AR-231,453 produced
sustained responses in a similar concentration range to those ob-
served with acute stimulation (a small 1.82 fold shift), with pEC50
values of 8.6770.11 and 8.9370.17, respectively. This suggests
that very little binding is lost upon washout of this ligand. In
marked contrast, AZ1 required higher concentrations to evoke a
sustained response relative to acute activation (a 95.50 fold shift in
the curves) with pEC50 values of 6.6370.17 and 8.6170.09, re-
spectively. Likewise, a large but less severe shift in concentration
responses (57.54 fold) was observed for MBX-2982 with respective
sustained and acute pEC50 values of 7.0370.13 and 8.7970.12.
This suggests that a large proportion of binding interactions with
AZ1 and MBX-2982 are lost by washing as for each concentration
applied at the beginning of the experiment there are less agonist
activated receptors at end.
As an alternative approach, time-course experiments were
conducted to examine the sustained effect duration of a single
concentration of agonist after its rapid removal by inﬁnite dilution.
We calculated that a single wash step (as described by the inﬁnite
dilution protocol in methods) could effectively dilute the agonist
when applied at maximally stimulating concentrations (30 nM;
based on acute responses; Fig. 5A–C) to a concentration without a
functional effect on receptor activation. This provided a means to
more directly measure the time-course of sustained effects with-
out complications of the time delay of multiple wash stages.
Fig. 5. Examining the longevity of wash-resistant cAMP responses to GPR119 agonists. (A–C) Concentration-dependent cAMP responses to AR-231,453 (A), MBX-2982
(B) and AZ1 (C) were measured in HEK-GPR119 cells. Acute responses (blue curves) were measured by incubation of the indicated agonist concentrations for 60 min at 37 °C
before addition of IBMX for a further 45 min at 20 °C. Sustained responses (red curves) were measured by pre-treatment with a range of agonist concentrations for 60 min
(37 °C), followed by washout of excess ligand and subsequent inclusion of IBMX for 45 min (20 °C). Responses are expressed as percentage of maximal (deﬁned as the
concentration giving the largest cAMP increase) (D) Inﬁnite dilution experiments with GPR119 agonists to investigate the time-course of sustained effects. HEK-GPR119 cells
were pre-treated with vehicle control (black), 30 nM AR-231,453 (red), MBX-2982 (blue) or AZ1 (green) for 60 min at 37 °C. Excess ligand was then removed by inﬁnite
dilution using a single wash step, and cells were incubated for the indicated times before addition of IBMX for a further 45 min to capture cAMP. (For interpretation of the
references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
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AZ1 (30 nM, 60 min, 37 °C) before agonist was removed by inﬁnite
dilution. Subsequently cells were incubated in drug-free buffer for
0, 1, 2, or 3 h at 20 °C before cellular cAMP levels were captured by
the addition of IBMX and measured by the endpoint assay
(Fig. 5D). AR-231,453, MBX-2982 and AZ1 pre-treated cells all
demonstrated signiﬁcantly elevated cAMP levels compared to
control cells for up to 3 h after inﬁnite dilution (Po0.05 or 0.01;
ANOVA; n¼3), indicating that sustained responses were main-
tained for at least this length of time.
3.5. Evidence for a role of membrane deposition in sustained re-
sponses to MBX-2982 and AZ1
The sustained wash-resistant GPR119 cAMP responses could be
explained by either slow dissociation kinetics (a direct receptor-
speciﬁc mechanism), rebinding (upon dissociation the ligand may
be more likely to re-associate with the receptor rather than diffuse
away and discontinue its inﬂuence (Vauquelin and Charlton,
2010)), and/or a membrane deposition (continual access of a li-
gand to the binding site due to plasma membrane accumulation in
the immediate vicinity of the receptor). Given the relatively high
log D for some of the compounds tested (Sup. Table S1) it was
predicted that the potential would exist for them to become in-
corporated into the membrane.
Differences in the sustained responses of MBX-2982 and AZ1
(but not AR-231,453) between chronic washout and inﬁnite dilu-
tion experiments provided the ﬁrst clues that rebinding/mem-
brane deposition may be important with these ligands. When theligand is removed by inﬁnite dilution, sustained receptor activa-
tion is maintained at a constant level for a number of hours
(Fig. 5D), whereas responses were clearly lost with the “chronic
incubation/washout” protocol (Fig. 5B and C). Indeed, we ﬁnd that
MBX-2982 and AZ1 concentrations incapable of causing a large
sustained effect in the “chronic incubation/washout” experiments
(30 nM; concentration–response analysis in Fig. 5B and C) can
cause a robust and sustained response in inﬁnite dilution experi-
ments (Fig. 5D). Therefore, it appears that multiple washes over
time (“chronic incubation/washout”) are more effective at re-
moving the effects of these agonists than single rapid wash step
(inﬁnite dilution), despite both approaches inﬁnitely diluting the
ligand. Consequently, the sustained responses to MBX-2982 and
AZ1 are not entirely dependent on free concentration of the ago-
nist in the surrounding buffer.
To more directly probe a role for such membrane interactions,
we reduced the potential for deposition of agonist molecules into
the membrane environment. By signiﬁcantly reducing the number
of molecules of agonist whilst maintaining the same agonist
concentration as well as number of cells, this approach will limit
the propensity for signiﬁcant membrane binding effects (Tesche-
macher and Lemoine, 1999). Through a minor adaptation to the
inﬁnite solution protocol described previously we pre-treated cells
with a greatly reduced volume of agonist-containing buffer at
0.05 ml instead of 12 ml (30 nM, 60 min, 37 °C) (Fig. 6A). Under
these conditions MBX-2982 and AZ1 failed to exhibit a sustained
wash-resistant response as cAMP accumulation captured after
inﬁnite dilution were not signiﬁcantly different to control cells
(P40.05; ANOVA; n¼3), indicating that the effect of these agonist
Fig. 6. Inﬁnite dilution experiments with pre-treatment of GPR119 agonists in a small volume. (A) Cells were pre-treated with vehicle control, 30 nM AR-231,453, MBX-2982
or AZ1 in a small volume of buffer (0.05 ml) for 60 min at 37 °C. Excess ligand was then removed using inﬁnite dilution by addition of a large volume of buffer, and then cells
were immediately exposed to IBMX to capture cAMP (45 min). (B) Cells were pre-treated with vehicle control or 30 nM AR-231,453 in a small volume of buffer (0.05 ml,
60 min, 37 °C), and cells washed via inﬁnite dilution by addition of fresh buffer. Cells were then incubated for the indicated times before addition of IBMX for a further 45 min
to capture cAMP.
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evoke a sustained response with cAMP levels signiﬁcantly higher
than control (Po0.01; ANOVA; n¼3). Moreover, when the long-
evity of these sustained effects of AR-231,453 were investigated
(by incubating in drug-free buffer for a range of times after inﬁnite
dilution) it was observed that cAMP levels remained signiﬁcantly
raised for at least 3 h (Po0.05; ANOVA compared to control cells
at each time-points; n¼3) (Fig. 6B), comparable to responses in a
large volume of buffer (Fig. 5D). These data are consistent with a
requirement for membrane deposition in the sustained wash-re-
sistant effects for MBX-2982 and AZ1, but not AR-231,453.Fig. 7. Dynamic cAMP measurements to examine the binding kinetics of GPR119 agon
responses. HEK-GPR119 cells transiently expressing GloSensor were incubated with 30 nM
vehicle control (blue lines) for a further 60 min, with cellular cAMP levels measured
responsiveness (at 10 and 60 min for AR-231,453 and AZ1, respectively). (C) Antagonist-m
pre-treated with 30 nM AR-231,453, MBX-2982, or AZ1 (60 min, 37 °C) before washing by
before IBMX added for a further 45 min to capture cAMP. Normalized data are express
control cells for each pre-treatment. (D) The effect of incubation time of AR-231,453 (re
cells transiently expressing GloSensor were incubated with a range of concentrations o
values were derived from the concentration–response curves analyzed at each time-poi
referred to the web version of this article.)3.6. Evidence for a role of slow binding kinetics in sustained re-
sponses to AR-231,453
As discussed above, membrane deposition does not appear to
drive the sustained signalling of AR-231,453. It is feasible that slow
dissociation kinetics and/or rebinding play a role. In the absence of
a suitable kinetic radioligand binding assay we indirectly assessed
agonist dissociation at the level of functional cAMP responses. By
measuring the rate of reversal of agonist responses by an an-
tagonist we could estimate agonist off-rate because competitive
displacement by antagonist requires agonist dissociation. As ago-
nist responses are relatively stable over time (Figs. 2 and 3), thisists. (A, B) Antagonist-mediated reversal of GPR119 agonist mediated acute cAMP
AR-231,453 (A) or AZ1 (B) for 60 min before addition of 1 mM ARN-II (red lines) or
at the indicated times. cAMP responses are expressed as percentage of maximal
ediated reversal of sustained cAMP responses using the endpoint assay. Cells were
inﬁnite dilution. Cells were then incubated with or without 1 mM ARN-II for 60 min
ed as percentage reduction of cAMP responses by inclusion of ARN-II compared to
d line) or AZ1 (blue line) on potency measurements was investigated. HEK-GPR119
f AR-231,453 or AZ1 and cAMP levels were measured at the indicated times. pEC50
nt. (For interpretation of the references to colour in this ﬁgure legend, the reader is
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responses. In the absence of a suitable neutral antagonist we used
the weak partial agonist ARN-II (ligand 9a in Semple et al. (2012)).
Cells were incubated with AR-231,453 (30 nM, 60 min, 20 °C)
before addition of 1 mM ARN-II or vehicle control (0.1% DMSO) for
a further 60 min, and cAMP levels measured at regular intervals
(Fig. 7A). Whilst ARN-II caused a small drop in cAMP levels evoked
by AR-231,453 stimulation, this was not signiﬁcantly different to
control at all time-points (P40.05; ANOVA; n¼3). In marked
contrast, when the receptor was activated with AZ1 (30 nM; ap-
proximately equipotent with applied AR-231,453 concentration),
cAMP responses were rapidly and robustly reversed by ARN-II
(Fig. 7B), with a signiﬁcant reduction in cAMP levels compared to
control after 10 min onwards exposure to ARN-II (Po0.001; AN-
OVA; n¼3). Reversal was nearly complete with AZ1 with re-
sponses at 10.5873.16% of maximal after 30 min antagonist ex-
posure. These ﬁndings are consistent with a much slower and less
complete dissociation of AR-231,453 compared to AZ1. Moreover,
they demonstrate that GPR119 cAMP responses measured using
this assay can be rapidly reversed under appropriate circum-
stances and the sustained GPR119 responses observed (Figs. 2B, D,
3B and 7A) are not an experimental artefact.
Using the endpoint assay, we next investigated the ability of
ARN-II to reverse the sustained responses of these ligands in
“chronic incubation/washout” experiments. In cells pre-treated
with AR-231,453, MBX-2982 or AZ1 (30 nM, 60 min, 37 °C), excess
agonist was removed by inﬁnite dilution and then incubated with
or without ARN-II (1 mM, 60 min, 20 °C). Sustained responses to
each agonist with and without subsequent ARN-II addition were
compared to calculate a percentage reversal (Fig. 7C). The sus-
tained response to AR-231,453 was reversed by 27.03710.04%,
whilst MBX-2982 and AZ1 were reversed to a signiﬁcantly greater
extent (Po0.01; ANOVA; n¼3) to 75.7076.34% and
62.5678.00%, respectively. These ﬁndings are consistent with
slower dissociation kinetics in AR-231,453 promoting its sustained
response, as little AR-231,453 is competitively displaced by ARN-II
in this setting. Moreover, the more robust reversal of MBX-2982
and AZ1 responses suggest faster dissociation kinetics, which is
consistent with membrane deposition being a prominent factor in
their sustained response proﬁle (the prolonged effects cannot be
explained by a single long-lived binding event, but instead by
multiple short-lived binding events that can be promoted by ac-
cumulation near the receptor).
To further assess the kinetic proﬁles of these agonists the in-
ﬂuence of incubation time on potency was measured by per-
forming concentration–response analysis at different time-pointsFig. 8. Acute and sustained GPR119-mediated GLP-1 secretion responses in GLUTag cells
inclusion of 1 μM agonist for 120 min at 37 °C without washout. (B) Sustained responses
pre-treatment (1 μM, 60 min, 37 °C) followed by washout. Responses are normalized tousing the GloSensor assay. It would be expected that a system
whereby the slow kinetics of receptor activation/deactivation
played a signiﬁcant role in the measurement potency would be
more sensitive to the effects of incubation time. Fig. 7D demon-
strates the relationship between pEC50 and time for AR-231,453 or
AZ1 in HEK-GPR119 cells using the GloSensor assay format high-
lighting a signiﬁcant shift of the pEC50 of AR-231,453from
6.9970.16 (102 nM) at 5 min to 8.1370.10 (7 nM) at 60 min. Po-
tency measured for AR-231,453 was signiﬁcantly higher at 60 min
compared to 5, 10, 20 (Po0.01), and 30 (Po0.05) min (ANOVA;
n¼3). In direct contrast, no signiﬁcant effect of time was observed
for potency measurements of AZ1 (60 min vs. all other time-
points; P40.05; ANOVA; n¼3). Moreover, little time effect on
pEC50 was observed for MBX-2982 (not shown). These potency
shifts with AR-231,453 are indicative of this ligand taking longer to
reach equilibrium, and therefore having slower binding kinetics.
Indeed dynamic traces of receptor activation observed in Glo-
Sensor experiments demonstrate slower responses for AR-231,453
compared to AZ1 (Fig. 7A and B).
3.7. Sustained responses in a physiologically relevant test system
We next investigated whether the observation of sustained
wash-resistant signalling also occurs at the level of physiologically
relevant functional responses in an endogenous cellular expres-
sion system. We therefore measured GLP-1 secretion in murine
GLUTag cells, which has previously been characterized as a
GPR119-mediated response (Lan et al., 2012). To conﬁrm GPR119
responses, plated cells were exposed to agonists (1 μM) in the
presence of the diepetidyl peptidase IV inhibitor K-579 (100 nM)
for 2 h at 37 °C, and ELISA was used to measure GLP-1 con-
centration in the supernatant. AR-231,453, MBX-2982, and AZ2
evoked a statistically signiﬁcant increase in GLP-1 secretion com-
pared to control cells (Po0.01 or 0.05; ANOVA; n¼4; Fig. 8A).
However, AZ1 failed to evoke a response. A likely explanation for
this is the species-speciﬁc pharmacology of some GPR119 agonists
(Scott et al., 2013); we are comparing mouse (GLUTag) and human
(HEK-GPR119) receptor responses.
We next investigated the propensity for sustained wash-re-
sistant receptor activation by pre-treating cells with 1 μM of these
agonists (60 min, 37 °C) and then washing out excess ligand. Post-
wash GLP-1 secretion was then measured by subsequent incuba-
tion in agonist-free buffer in the presence of K-579 for 2 h at 37 °C.
In these experiments, only AR-231,453 evoked a residual receptor
response that was higher than control cells (Po0.05; ANOVA;
n¼3; Fig. 8B). Although there was a trend towards increased. (A) Acute responses were monitored by measuring GLP-1 secretion stimulated by
were monitored by measuring GLP-1 secretion over 120 min at 37 °C after agonist
vehicle control (white bars) in each case.
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Therefore, sustained wash-resistant receptor activation can
translate to a functional read-out in an endogenous expression
system, although not all agonists identiﬁed as sustained in our
recombinant system displayed this behaviour. Perhaps this is
linked to AR-231,453 responses being more robust, durable and
less susceptible to exposure conditions (e.g. incubation volume)
compared to MBX-2982. The responses window for GPR119 sig-
nalling in this GLUTag cell assay was small, which may hinder the
observation of low-level sustained responses.4. Discussion
In this study we have investigated the temporal dynamics of
GPR119 signalling and have found that chronic incubation of
agonists permits stable activation of the receptor. Moreover, ago-
nist-speciﬁc factors that we propose can delay the termination of
agonist/receptor interactions (slow off-rate or membrane deposi-
tion) cause sustained wash-resistant receptor activation, persisting
for at least a number of hours.
Classic understanding of GPCR signalling is described by a
gradual loss of receptor responsiveness after prolonged agonist
exposure caused by desensitization and internalization via β‐ar-
restin‐dependent mechanisms (Drake et al., 2006; Kelly et al.,
2008). However, we ﬁnd that in our test system, desensitization is
not a major regulatory inﬂuence on GPR119 function as little/no
loss of cAMP response is observed with chronic agonist exposure.
Direct reports of GPR119 desensitization in the literature are lim-
ited, although a recent study demonstrated desensitization of
calcium responses by novel and existing GPR119 agonists using re-
stimulation experiments (Zhang et al., 2014). This need not be
inconsistent with our ﬁndings as pathway-speciﬁc or agonist-
speciﬁc desensitization mechanisms potentially play. Additionally,
the kinetics of the calcium response and levels of receptor reserve
may also contribute to the observed differences in desensitization
proﬁle between these systems. A second recent report suggested
that both AR-231,453 and oleoylethanolamide evoke complete
desensitization of GPR119 cAMP responses (Kumar et al., 2014).
However, in these experiments the investigators did not appear to
wash out excess ligand before challenging with a second stimulus,
which may preclude the observation of re-stimulation responses
and therefore confound the observation of true desensitization. To
our knowledge, this is the ﬁrst direct and comprehensive in-
vestigation of agonist-mediated desensitization of GPR119 cAMP
responses. A number of other GPCR systems have also been re-
ported to show no loss of responsiveness upon chronic stimulation
with agonist (Calebiro et al., 2009; Callander et al., 2009; Ferran-
don et al., 2009; Jensen et al., 2013; Mullershausen et al., 2009;
Willars et al., 1999).
We cannot rule out desensitization at very high agonist con-
centrations, as this was observed in some cases with supramax-
imal stimulation in an assay-speciﬁc manner. Lauffer et al. (2009)
speculated that bell-shaped concentration–responses curves to
GPR119 agonists indicate receptor desensitization at high con-
centrations. Indeed, we also observe bell-shaped curves for some
agonists. It is plausible that supramaximal concentrations of ago-
nists evoke desensitization by either non-conventional mechan-
isms or due to low afﬁnity interactions with β-arrestin-coupled
conformations of the receptor. Nevertheless, robust receptor acti-
vation is still observed after chronic exposure to pharmacologically
relevant concentrations of our test agonists.
For some agonists, these stable GPR119 responses were re-
sistant to washing. Thus, sustained activation could continue, for at
least a number of hours, even after removal of free agonist. These
data are consistent with reports for other GPCR systems that donot desensitize (Calebiro et al., 2009; Ferrandon et al., 2009;
Mullershausen et al., 2009).
The simplest explanation for the observation of sustained
wash-resistant responses is slow agonist dissociation kinetics,
where a single long-lived binding interaction continues long after
removal of unbound ligand by washing. Our ﬁndings are con-
sistent with an involvement of binding kinetics in the sustained
effects of AR-231,453. The strongest evidence came from an in-
ability of antagonist to reverse AR-231,453-mediated GPR119 ac-
tivation. In the presence of a saturating concentration of antago-
nist it would be expected that if agonist molecules dissociate, the
binding site would become occupied by antagonist thereby pre-
venting future receptor activation. Since the antagonist fails to
interrupt receptor activation, this suggests that AR-231,453 re-
mains bound to the receptor, without dissociating, throughout the
generation of the sustained responses. These experiments in-
directly monitor agonist binding kinetics as a downstream func-
tional response. Therefore, it would be advantageous to perform
follow up studies that directly probe occupation of the binding site
(e.g. radioligand binding), when these become available. Compar-
ison of the concentration–response relationship before and after
washing demonstrates little effect of removal of unbound ligand.
This suggests the presence of stable agonist interactions within the
receptor binding site, rather than a secondary requirement for
nonspeciﬁc interactions with membrane sites which if involved
would likely impact the temporal characteristics of receptor acti-
vation. In support of this assumption we found little evidence for a
requirement for membrane deposition of AR-231,453. Whilst a
direct analysis of the binding kinetics of AR-231,453 would be
highly desirable to validate a role for long residence time in its
sustained effects, we currently lack the tools to establish such an
assay.
Much of the emphasis in the literature is focused on the role of
receptor binding kinetics in antagonist function. However, whilst
an understanding and role for GPCR agonist binding kinetics is
largely overlooked, there is some precedent for this effect in the
literature. Sustained receptor responses linked to agonists with
slow dissociation rates have been reported for the calcitonin
(Andreassen et al., 2014), parathyroid hormone (Dean et al., 2008;
Ferrandon et al., 2009; Okazaki et al., 2008), mealocortin (Haskell-
Luevano et al., 1996) and muscarinic M1 (Jakubik et al., 2002)
receptors.
An inability of washing/dilution to successfully remove the
agonist from the vicinity of the receptor, rather than persistent
occupation of the receptor binding site per se is an alternative
mechanism to explain sustained wash-resistant signalling. Re-
binding, where upon dissociation from the receptor an agonist is
more likely to bind again than diffuse away and discontinue its
inﬂuence (Vauquelin and Charlton, 2010); or membrane deposi-
tion, where cellular membranes act as a reservoir of the agonist
that can later access the receptor binding site (Anderson et al.,
1994) have both been postulated to play a role in sustained wash-
resistant agonist responses. A key distinction between the roles of
binding kinetics and rebinding/membrane deposition is that the
former involves pre-established binding interactions formed dur-
ing the initial agonist incubation that remain after removal of
unbound ligand, whilst the latter relies on new binding interac-
tions being made after removal of excess ligand as unbound ligand
is not effectively removed by dilution of drug in the surrounding
ﬂuid. These post-washing binding events can be identiﬁed by re-
sponses that are readily reversed by antagonist. As the responses
to MBX-2982 and AZ1 were reversed by antagonist, this suggests
that agonist dissociation events occur over the time-course of the
experiments as receptor binding sites are left unoccupied for an-
tagonist binding. Our observations that rapid washing (inﬁnite
dilution protocol) was less effective than many washes over time
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with rebinding/membrane deposition being involved in the sus-
tained effects of the agonists MBX-2982 and AZ1 as they high-
lighted that free concentration of the ligand was not the only
factor driving the effect. Moreover, these ﬁndings indicate that
receptor-independent mechanisms are involved, and cannot be
explained by binding kinetics alone.
Evidence that membrane deposition of MBX-2982 and AZ1 may
play a prominent role over rebinding come from ﬁndings that the
sustained effects are sensitive to a reduction in buffer volume
during chronic pre-treatment, suggesting that a large number of
agonist molecules are needed to evoke the response via their ac-
cumulation in cell membranes (Teschemacher and Lemoine, 1999).
High lipophilicity is often cited as a key determinant in ligand
membrane deposition as it favours interactions with lipid mem-
branes. Indeed we ﬁnd that the lipophilicity (log D values) and
protein binding of MBX-2982 and AZ1 are high (Sup. Table S1) and
could accommodate this role. However, other agonists that do not
exert a sustained wash-resistant effect also have high lipophilicity
(e.g. AZ2), so this is unlikely to be the sole mechanism. Membrane
deposition has been proposed as a mechanism of the prolonged
cellular and clinical effects of long-acting β2-adrenergic receptor
agonists such as salmeterol (Anderson et al., 1994; Szczuka et al.,
2009; Teschemacher and Lemoine, 1999).
Whilst a number of GPR119 agonists, including GSK-1292263
and MBX-2982, have advanced to phase II clinical trials for type-2
diabetes, it appears that a common problem with these ligands
may be a lack of clinical efﬁcacy (Kang, 2013). Indeed, clinical
development of GSK-1292263 has been discontinued. It is tempt-
ing to speculate that efﬁcacy could be improved by targeting li-
gands with enhanced sustained effects, as this could provide more
prolonged receptor signalling. There is a growing appreciation that
targeting ligands with a long residence time could be useful
strategy in drug discovery for increased target coverage and de-
creased toxicity (Copeland et al., 2006; Guo et al., 2014). We ﬁnd
that the sustained effects of GSK-1292263 are weak and not sta-
tistically signiﬁcant, and may therefore limit its ability to activate
GPR119 in a physiological setting. Although MBX-2982 did cause
robust sustained wash-resistant receptor activation, the effects
with AR-231,453 were higher in magnitude (Fig. 4A), as well as
being more stable, more potent and less susceptible to exposure
conditions (Figs. 5 and 6). Encouragingly, for AR-231,453 we also
observe sustained responses downstream of cAMP in an en-
dogenous expression system, which supports the potential (patho)
physiological relevance of this phenomena.
This study highlight the importance of carefully examining the
mechanisms through which G protein-coupled receptor agonists
generate their temporal response proﬁles and could identify ex-
citing opportunities to exploit these responses with pharmacolo-
gical agents. Clearly, further work is needed to assess the chronic
effects of GPR119 agonists on their clinical efﬁcacy and to deﬁne
the desired temporal proﬁle of target activation as well mechan-
ism of action (binding kinetics vs. rebinding/membrane deposi-
tion), with the potential to develop improved pharmacotherapies
for this target.5. Conclusions
We have demonstrated that in a recombinant expression sys-
tem GPR119 responses at the level of cAMP signalling are under
minimal inﬂuence from desensitization at pharmacologically re-
levant agonists concentrations. Furthermore we identiﬁed a
compound speciﬁc (AR-231,453, MBX-2982, and AZ1) sustained
GPR119 activation proﬁle that was insensitive to extensive wash-
ing to remove unbound ligand. Our data support that multiplemechanisms, including slow dissociation kinetics (AR-231,453), or
membrane deposition and rebinding (MBX-2982 and AZ1) may
contribute to wash-resistant signalling. Importantly, sustained ef-
fects of AR-231,453 were also observed at the level of physiological
responses in an endogenous cellular expression system.Acknowledgements
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